Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,942 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dose modification in enzalutamide and abiraterone plus prednisolone for castration-resistant prostate cancer: A subanalysis from the ENABLE study for PCa.
Tanaka N, Izumi K, Nakai Y, Shima T, Kato Y, Mita K, Kamiyama M, Inoue S, Hoshi S, Okamura T, Yoshio Y, Enokida H, Chikazawa I, Kawai N, Hashimoto K, Fukagai T, Shigehara K, Takahara S, Mizokami A. Tanaka N, et al. Among authors: inoue s. Prostate. 2024 Sep 20. doi: 10.1002/pros.24796. Online ahead of print. Prostate. 2024. PMID: 39301921
Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial.
Izumi K, Mizokami A, Namiki M, Inoue S, Tanaka N, Yoshio Y, Ishibashi K, Kamiyama M, Kawai N, Enokida H, Shima T, Takahara S. Izumi K, et al. Among authors: inoue s. BMC Cancer. 2017 Oct 10;17(1):677. doi: 10.1186/s12885-017-3661-2. BMC Cancer. 2017. PMID: 29017493 Free PMC article. Clinical Trial.
Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial.
Izumi K, Shima T, Mita K, Kato Y, Kamiyama M, Inoue S, Tanaka N, Hoshi S, Okamura T, Yoshio Y, Enokida H, Chikazawa I, Kawai N, Hashimoto K, Fukagai T, Shigehara K, Takahara S, Kadono Y, Mizokami A. Izumi K, et al. Among authors: inoue s. Eur Urol Open Sci. 2022 May 19;41:16-23. doi: 10.1016/j.euros.2022.04.016. eCollection 2022 Jul. Eur Urol Open Sci. 2022. PMID: 35813251 Free PMC article.
Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa.
Mita K, Izumi K, Goriki A, Tasaka R, Hatayama T, Shima T, Kato Y, Kamiyama M, Inoue S, Tanaka N, Hoshi S, Okamura T, Yoshio Y, Enokida H, Chikazawa I, Kawai N, Hashimoto K, Fukagai T, Shigehara K, Takahara S, Kadono Y, Mizokami A. Mita K, et al. Among authors: inoue s. Cancers (Basel). 2024 Jan 24;16(3):508. doi: 10.3390/cancers16030508. Cancers (Basel). 2024. PMID: 38339260 Free PMC article.
Predictors of poor response to first-generation anti-androgens as criteria for alternate treatments for patients with non-metastatic castration-resistant prostate cancer.
Fukuoka K, Teishima J, Nagamatsu H, Inoue S, Hayashi T, Mita K, Shigeta M, Kobayashi K, Kajiwara M, Kadonishi Y, Tacho T, Matsubara A. Fukuoka K, et al. Among authors: inoue s. Int Urol Nephrol. 2020 Jan;52(1):77-85. doi: 10.1007/s11255-019-02281-4. Epub 2019 Sep 24. Int Urol Nephrol. 2020. PMID: 31552574
FGF19 promotes progression of prostate cancer.
Nagamatsu H, Teishima J, Goto K, Shikuma H, Kitano H, Shoji K, Inoue S, Matsubara A. Nagamatsu H, et al. Among authors: inoue s. Prostate. 2015 Jul 1;75(10):1092-101. doi: 10.1002/pros.22994. Epub 2015 Apr 8. Prostate. 2015. PMID: 25854696
Impact of neutrophil-to-lymphocyte ratio on effects of targeted therapy for metastatic renal cell carcinoma patients with extrapulmonary metastasis.
Teishima J, Ohara S, Sadahide K, Fujii S, Kitano H, Kobatake K, Shinmei S, Hieda K, Inoue S, Hayashi T, Mita K, Matsubara A. Teishima J, et al. Among authors: inoue s. Can Urol Assoc J. 2017 May;11(5):E207-E214. doi: 10.5489/cuaj.4106. Epub 2017 May 9. Can Urol Assoc J. 2017. PMID: 28503236 Free PMC article.
Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival.
Teishima J, Ohara S, Shinmei S, Inoue S, Hayashi T, Mochizuki H, Mita K, Shigeta M, Matsubara A. Teishima J, et al. Among authors: inoue s. Urol Oncol. 2018 Jul;36(7):339.e9-339.e15. doi: 10.1016/j.urolonc.2018.04.008. Urol Oncol. 2018. PMID: 29773493
Impact of the systemic immune-inflammation index for the prediction of prognosis and modification of the risk model in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors.
Teishima J, Inoue S, Hayashi T, Mita K, Hasegawa Y, Kato M, Kajiwara M, Shigeta M, Maruyama S, Moriyama H, Fujiwara S, Matsubara A. Teishima J, et al. Among authors: inoue s. Can Urol Assoc J. 2020 Nov;14(11):E582-E587. doi: 10.5489/cuaj.6413. Can Urol Assoc J. 2020. PMID: 32520703 Free PMC article.
5,942 results